Benutzer: Gast  Login
Dokumenttyp:
Article
Autor(en):
Fenaux, Pierre; Santini, Valeria; Spiriti, Maria Antonietta Aloe; Giagounidis, Aristoteles; Schlag, Rudolf; Radinoff, Atanas; Gercheva-Kyuchukova, Liana; Anagnostopoulos, Achilles; Oliva, Esther Natalie; Symeonidis, Argiris; Berger, Mathilde Hunault; Goetze, Katharina S.; Potamianou, Anna; Haralampiev, Hari; Wapenaar, Robert; Milionis, Iordanis; Platzbecker, Uwe
Titel:
A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-alpha in anemic patients with low-risk MDS
Abstract:
Erythropoiesis-stimulating agents are first choice for treating anemia in low-risk MDS. This double-blind, placebo-controlled study assessed the efficacy and safety of epoetin-alpha in IPSS low- or intermediate-1 risk (i.e., low-risk) MDS patients with Hb <= 10.0 g/dL, with no or moderate RBC transfusion dependence (<= 4 RBC units/8 weeks). Patients were randomized, 2:1, to receive epoetin-alpha 450 IU/kg/week or placebo for 24 weeks, followed by treatment extension in responders. The primary endpoint was erythroid response (ER) through Week 24. Dose adjustments were driven by weekly Hb-levels and included increases, and dose reductions/discontinuation if Hb > 12 g/dL. An independent Response Review Committee (RRC) blindly reviewed all responses, applying IWG-2006 criteria but also considering dose adjustments, drug interruptions and longer periods of observation. A total of 130 patients were randomized (85 to epoetin-alpha and 45 to placebo). The ER by IWG-2006 criteria was 31.8% for epoetin-alpha vs 4.4% for placebo (p < 0.001); after RRC review, the ER was 45.9 vs 4.4% (p < 0.001), respectively. Epoetin-alpha reduced RBC transfusions and increased the time-to-first-transfusion compared with placebo. Thus, epoetin-alpha significantly improved anemia outcomes in low-risk MDS. IWG-2006 criteria for ER may require amendments to better apply to clinical studies.
Zeitschriftentitel:
Leukemia
Jahr:
2018
Band / Volume:
32
Heft / Issue:
12
Seitenangaben Beitrag:
2648-2658
Volltext / DOI:
doi:10.1038/s41375-018-0118-9
PubMed:
http://view.ncbi.nlm.nih.gov/pubmed/29895954
Print-ISSN:
0887-6924
TUM Einrichtung:
III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie)
 BibTeX